NEW YORK, May 17, 2025 /PRNewswire/ -- Julie & Holleman LLP, a top-tier shareholder rights firm, is investigating potential claims against Iovance  Biotherapeutics, Inc. (Nasdaq: IOVA) and its executives for recent losses suffered by the company's stockholders.For a free consultation, please visit https://julieholleman.com/iovance-biotherapeutics-inc/. You may also contact partner Scott Holleman at (929) 415-1020 or by email at [email protected].According to a complaint recently filed in federal court, Iova ...

SAN DIEGO, May 16, 2025 /PRNewswire/ -- Robbins LLP informs stockholders that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) securities between May 9, 2024 and May 8, 2025. Iovance is a commercial-stage biopharmaceutical company which develops and commercializes cell therapies for the treatment of metastatic melanoma and other solid tumor cancers.For more information, submit a form, email attorney Aaron Dumas, ...

NEW YORK, May 16, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (NASDAQ:IOVA) in the United States District Court for the Northern District of California on behalf of all persons and entities who purchased or otherwise acquired Iovance securities between May 9, 2024 and May 8, 2025, both dates inclusive (the “Class Period”). Inve ...

NEW YORK, May 16, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Northen District of California on behalf of all persons or entities who purchased or otherwise acquired Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (NASDAQ: IOVA) securities between May 9, 2024 and May 8, 2025, inclusive (the “Class Period”). The lawsuit seeks to recover damages for the Company’s investors under the fe ...

Iovance Biotherapeutics (IOVA -5.68%) didn't quite end the stock trading week on a high note. The company's shares were dinged by almost 6% that day, due largely to an analyst's recommendation downgrade. This occurred on a generally positive day for equities, as the S&P 500 index managed to land in the black with a 0.7% rise.A bearish adjustmentWell before market open, UBS pundit David Dai flipped the switch on his Iovance recommendation, changing it to neutral from his previous buy. Compounding that signif ...

NEW YORK, May 16, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Iovance Biotherapeutics, Inc. (“Iovance” or “the Company”) (NASDAQ: IOVA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired I ...

ATLANTA, May 16, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (NASDAQ: IOVA). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information about Iovance’s business, operations, and prospects, including allegations that: (1) new Authorized Treatment Centers (“ATCs”) were experiencing longer timelines to begin treating patients with A ...

NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (NASDAQ: IOVA) between August 8, 2024, to May 8, 2025, both dates inclusive. You are hereby notified that the class action lawsuit Karthik Trichur Sundaram v. Iovance Biotherapeutics, Inc., et al. (Case No. 3:25-cv-04177) has been commenced in the United States Dist ...

Iovance's poor first quarter Penny stocks -- companies with shares trading at around $5 or even less apiece -- usually carry above-average risk. However, there may be hidden gems among them: companies with attractive prospects that continue to be ignored by most investors. Identifying those penny stocks with significant latent upside potential and investing in them before they catch fire can lead to life-changing returns. That brings us to Iovance Biotherapeutics (IOVA -5.03%), a small-cap biotech that has ...

公司财务表现 - Iovance Biotherapeutics 2025年第一季度总产品收入为4930万美元 较上一季度的7370万美元显著下降 [2] - 公司大幅下调2025财年总产品收入指引 从原预期的4.5亿-4.75亿美元降至2.5亿-3亿美元 中值降幅超过40% [2] 产品动态 - 下调收入指引源于T细胞免疫疗法Amtagvi®(lifileucel)近期上市表现 该产品于2024年上半年在美国商业化推出 [2] 市场反应 - 财务指引调整后 Iovance股票在异常高成交量下出现下跌 [2] 法律调查 - Bragar Eagel & Squire律师事务所正在调查Iovance是否违反联邦证券法或其他非法商业行为 [1]